C4 Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on April 9, 2026, regarding events occurring on April 8, 2026. C4 Therapeutics, Inc. (C4T), a biopharmaceutical company focused on targeted protein degradation, announced a new strategic collaboration.
Key Financial Metrics and Transaction Details
The filing details a Research Collaboration and License Agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Roche). Key financial terms include:
- Upfront Payment: $20.0 million cash payment from Roche to C4T.
- Milestone Payments: C4T is eligible to receive over $1.0 billion in aggregate development, regulatory, and commercial milestone payments.
- Royalties: Tiered royalties on net sales ranging from mid-single digit to low-double digit percentages.
- Cost Responsibility: Roche is responsible for all development, regulatory approval, manufacturing, and commercialization costs.
- Scope: The agreement covers two initial undisclosed oncology targets with an option for one additional target.
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the company's general operations, as this is a transaction-specific report.
Material Changes
This agreement represents a material expansion of the pre-existing relationship between C4T and Roche, which began in 2016. The new agreement grants Roche a worldwide, exclusive license under certain C4T intellectual property rights for Degrader-Antibody Conjugates (DACs).
Outlook, Risks, and Contingencies
Management Commentary: The collaboration focuses on DACs, an emerging modality designed to selectively target and neutralize disease-causing proteins in cancer cells.
Termination Rights:
- Either party may terminate for material breach or insolvency.
- Roche may terminate the agreement in its entirety or on a target-by-target basis for convenience upon 90 days' notice.
Contingencies: Future payments are contingent upon the achievement of specified research and development milestones and the generation of net sales. The option for an additional target is exercisable within a specified period subject to an option exercise fee.
Key Facts for Investor Verification
- Verify the receipt of the $20.0 million upfront payment in the next quarterly financial report.
- Confirm the specific identity of the two initial oncology targets and the terms of the option for the third target.
- Review the detailed milestone definitions and royalty reduction clauses in the full License Agreement (to be filed as an exhibit to the Form 10-Q for the period ending June 30, 2026).
- Assess the impact of the 90-day termination for convenience clause on the valuation of future milestone payments.